New Two-Drug attack on advanced throat cancer begins testing
NCT ID NCT07267338
Summary
This study is testing whether adding two immunotherapy drugs (pembrolizumab and MRG-003) before and after standard chemoradiation can better control advanced nasopharyngeal cancer. It will involve about 35 adults with a specific type of this cancer linked to the Epstein-Barr virus. The goal is to see if this combination leads to a complete disappearance of detectable cancer and improves survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NPC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Xiehe Hospital
Wuhan, Hubei, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.